Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial
Key facts
- Who runs it
- The Third Affiliated Hospital of Southern Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 276 people, planned
- Started
- 18 Mar 2026
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- LUSE-TLIF
- MIS-TLIF
- Record updated
- 14 May 2026
Who can take part
- Age
- 40 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ranging from 40 to 70 years, irrespective of sex
- Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain
- Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and/or lumbar instability
- Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months
- Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule
Who cannot take part
- Patients with a history of previous lumbar spine surgery
- Known concurrent diseases considered by the investigator to preclude study entry
- Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases
- Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure
- Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound
- Pregnancy or lactation
- Inability to comply with study assessments or complete questionnaires for any reason
- Patients deemed unsuitable for participation in this trial as judged by the investigator
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. For patients who do not respond to conservative treatment, surgical intervention remains a key therapeutic approach, with lumbar interbody fusion (LIF) being a commonly employed procedure. The technique has evolved from posterior lumbar interbody fusion (PLIF) to transforaminal lumbar interbody fusion (TLIF) and, more recently, to minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Although MIS-TLIF can effectively reduce tissue trauma and complications, it still faces clinical challenges such as intraoperative visual blind spots and the potential for postoperative chronic back pain associated with reliance on conventional pedicle screws. To address these limitations, our research team independently developed a highly integrated, miniaturized (with an outer diameter of only 1.8 mm), and maneuverable L-Unitary Soft Endoscope (LUSE) minimally invasive system. Its unique design helps avoid obstruction of the surgical field and allows flexible adjustment during the procedure. Currently, there is a lack of clinical efficacy evaluations in China on the use of this LUSE system for TLIF surgery (referred to as LUSE-TLIF) in treating LSS. Therefore, this study aims to systematically compare LUSE-TLIF with the currently mainstream MIS-TLIF, evaluating its safety, efficacy, and clinical outcomes in the treatment of LSS, in order to provide spine surgeons with a novel and potentially superior minimally invasive surgical option.
The 2 groups in the trial
- LUSE-TLIFTreatment being tested
The subject underwent LUSE-TLIF surgery
- MIS-TLIFExisting treatment, for comparison
Subjects underwent MIS-TLIF surgery assisted by the Quadrant channel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Analysis of L-Unitary Soft Endoscope Transforaminal Lumbar Interbody Fusion (LUSE-TLIF) Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial
- Criteria questions
- Built from NCT07588555, who can take part
- Record updated
- 14 May 2026